edaravone has been researched along with Cardiac Failure in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "During the development of heart failure, edaravone ameliorated the defective interdomain interaction of the RyR2." | 3.73 | Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. ( Doi, M; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Mochizuki, M; Noma, T; Oda, T; Ohkusa, T; Okuda, S; Tateishi, H; Tokuhisa, T; Yamamoto, T; Yano, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, Y | 1 |
| Yamada, Y | 1 |
| Shimomura, H | 1 |
| Nagayoshi, Y | 1 |
| Tsujita, K | 1 |
| Yamashita, T | 1 |
| Fukuda, M | 1 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 1 |
| Sugiyama, S | 1 |
| Ogawa, H | 1 |
| Yano, M | 1 |
| Okuda, S | 1 |
| Oda, T | 1 |
| Tokuhisa, T | 1 |
| Tateishi, H | 1 |
| Mochizuki, M | 1 |
| Noma, T | 1 |
| Doi, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ikeda, Y | 1 |
| Ohkusa, T | 1 |
| Ikemoto, N | 1 |
| Matsuzaki, M | 1 |
1 trial available for edaravone and Cardiac Failure
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
1 other study available for edaravone and Cardiac Failure
| Article | Year |
|---|---|
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure.
Topics: Animals; Antioxidants; Antipyrine; Calcium; Cardiac Pacing, Artificial; Dogs; Edaravone; Heart Failu | 2005 |